International audience
-
April 2017 (v1)Journal articleUploaded on: December 4, 2022
-
May 15, 2017 (v1)Journal article
We recently described a new family of bioactive molecules with interesting anti-cancer activities: the N-(4-(3-aminophenyl)thiazol-2-yl)acetamides. The lead compound of the series (1) displays significant anti-proliferative and cytotoxic activities against a panel of cancer cell lines, either sensitive or resistant to standard treatments. This...
Uploaded on: February 28, 2023 -
July 12, 2021 (v1)Journal article
Four novel arylbiamidine series were studied showing particular tautomerism and H-bonding structure highlighting their promising druglike features toward anticancer applications.
Uploaded on: February 22, 2023 -
July 12, 2021 (v1)Journal article
Four novel arylbiamidine series were studied showing particular tautomerism and H-bonding structure highlighting their promising druglike features toward anticancer applications.
Uploaded on: December 4, 2022 -
July 12, 2021 (v1)Journal article
Four novel arylbiamidine series were studied showing particular tautomerism and H-bonding structure highlighting their promising druglike features toward anticancer applications.
Uploaded on: December 4, 2022 -
July 2021 (v1)Journal article
Background: In line with our recent discovery of an efficient anticancer thiazolebenzenesulfonamide framework HA15 (1) based on a remarkable endoplasmic reticulum stress inducement mode of action, we report herein a series of innovative constrained HA15 analogs, featuring four types of bicylic derivatives. Results: The structure–activity...
Uploaded on: December 4, 2022 -
December 2017 (v1)Journal article
There is a growing body of evidence about the presence and the activity of the miRISC in the nucleus of mammalian cells. Here, we show by quantitative proteomic analysis that Ago2 interacts with the nucleoplasmic protein Sfpq in an RNA-dependent fashion. By a combination of HITS-CLIP and transcriptomic analyses, we demonstrate that Sfpq...
Uploaded on: December 4, 2022 -
May 2018 (v1)Journal article
Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeutical approaches to bypass resistance and...
Uploaded on: December 4, 2022